Inosine pranobex (IP), commonly known as inosine acedoben dimepranol, isoprinosine and methisoprinol, has been proven to positively impact the host's immune system, by enhancing T-cell lymphocyte proliferation and activity of natural killer cells, increasing levels of pro-inflammatory cytokines, and thereby restoring deficient responses in immunosuppressed patients. At the same time, it has been shown that it can affect viral RNA levels and hence inhibit growth of several viruses. Due to its immunomodulatory and antiviral properties, and its safety profile, it has been widely used since 1971 against viral infections and diseases, among which subacute sclerosis panencephalitis, herpes simplex virus, human papilloma virus, human immunodeficiency virus, influenza and acute respiratory infections, cytomegalovirus and Epstein-Barr virus infections. Following an analysis of almost five decades of scientific literature since its original approval, we here summarize in vivo and in vitro studies manifesting the means in which IP impacts the host's immune system. We also provide a synopsis of therapeutic trials in the majority of which IP was found to have a beneficial effect. Lastly, positive results from limited studies, suggesting the putative future use of IP in new therapeutic indications are briefly described. In order to support use of IP against viral infections apart from those already approved, and to establish its use in clinical practice, further well-designed and executed trials are warranted.Funding: Ewopharma International.

Department of Pharmacology 3rd Faculty of Medicine Charles University Prague Czech Republic

Institute of Pharmacovigilance Prague Czech Republic

See more in PubMed

Wybran J, Appelboom T. Immunomodulation. Boston, MA: Springer; 1984. Isoprinosine (inosiplex): immunological and clinical effects; pp. 363–374.

Masihi KN. Principles of immunopharmacology. Basel: Birkhäuser; 2011. C7 Anti-infective activity of immunomodulators; pp. 411–435.

You Y, Wang L, Li Y, Wang Q, Cao S, Tu Y, et al. Multicenter randomized study of inosine pranobex versus acyclovir in the treatment of recurrent herpes labialis and recurrent herpes genitalis in Chinese patients. J Dermatol. 2015;42(6):596–601. PubMed

Brzeski M, Madhok R, Hunter JA, Capel HA. Randomised, double blind, placebo controlled trial of inosine pranobex in rheumatoid arthritis. Ann Rheum Dis. 1990;49:293–295. PubMed PMC

Majewska A, Lasek W, Janyst M, Mlynarczyk G. In vitro inhibition of HHV-1 replication by inosine pranobex and interferon-α. Acta Pol Pharm. 2016;73(3):637–644. PubMed

Tobolska S, Terpilowska S, Jaroszewski J, Siwicki AK. Genotoxicity and mutagenicity of inosine pranobex. J Vet Res. 2018;62(2):207–213. PubMed PMC

Tobólska S, Terpiłowska S, Jaroszewski J, Siwicki AK. Influence of inosine pranobex on cell viability in normal fibroblasts and liver cancer cells. J Vet Res. 2018;62(2):215–220. PubMed PMC

Hadden J, Wybran J, editors. Immunopotentiators II Isoprinosine, NPT 15392 and Azimexone: modulators of lymphocyte and macrophage development and function. Advances in Immunopharmacology: Proceedings of the First International Conference on Immunopharmacology; 1981: Elsevier.

Petrova M, Jelev D, Ivanova A, Krastev Z. Isoprinosine affects serum cytokine levels in healthy adults. J Interferon Cytokine Res. 2010;30(4):223–228. PubMed

Lasek W, Janyst M, Wolny R, Zapala L, Bocian K, Drela N. Immunomodulatory effects of inosine pranobex on cytokine production by human lymphocytes. Acta Pharm. 2015;65(2):171–180. PubMed

Milano S, Dieli M, Millott S, Miceli MD, Maltese E, Cillari E. Effect of isoprinosine on IL-2, IFN-gamma and IL-4 production in vivo and in vitro. Int J Immunopharmacol. 1991;13(7):1013–1018. PubMed

Tsang KY, Pan JF, Swanger DL, Fudenberg HH. In vitro restoration of immune responses in aging humans by isoprinosine. Int J Immunopharmacol. 1985;7(2):199–206. PubMed

Tsang KY, Fudenberg HH, Pan JF, Gnagy MJ, Bristow CB. An in vitro study on the effects of isoprinosine on immune responses in cancer patients. Int J Immunopharmacol. 1983;5(6):481–490. PubMed

Sabat R, Grutz G, Warszawska K, Kirsch S, Witte E, Wolk K, et al. Biology of interleukin-10. Cytokine Growth Factor Rev. 2010;21(5):331–344. PubMed

Ahmed RS, Newman AS, O’Daly J, Duffy S, Grafton G, Brady CA, et al. Inosine acedoben dimepranol promotes an early and sustained increase in the natural killer cell component of circulating lymphocytes: a clinical trial supporting anti-viral indications. Int Immunopharmacol. 2017;42:108–114. PubMed

Balestrino C, Montesoro E, Nocera A, Ferrarini M, Hoffman T. Augmentation of human peripheral blood natural killer activity by methisoprinol. J Biol Response Modif. 1983;2(6):577–585. PubMed

Diaz-Mitoma F, Turgonyi E, Kumar A, Lim W, Larocque L, Hyde BM. Clinical improvement in chronic fatigue syndrome is associated with enhanced natural killer cell-mediated cytotoxicity: the results of a pilot study with Isoprinosine®. J Chronic Fatigue Syndr. 2003;11(2):71–95.

Bekesi JG, Tsang PH, Wallace JI, Roboz JP. Immunorestorative properties of isoprinosine in the treatment of patients at high risk of developing ARC or AIDS. J Clin Lab Immunol. 1987;24(4):155–161. PubMed

Hersey P, Edwards A. Effect of isoprinosine on natural killer cell activity of blood mononuclear cells in vitro and in vivo. Int J Immunopharmacol. 1984;6(4):315–320. PubMed

Ohnishi H, Kosuzume H, Inaba H, Ohkura M, Shimada S, Suzuki Y. The immunomodulatory action of inosiplex in relation to its effects in experimental viral infections. Int J Immunopharmacol. 1983;5(3):181–196. PubMed

De Simone C, Ricca D, Sorice F. In vitro influence of methisoprinol on human eosinophils. Int J Immunopharmacol. 1982;4(4):369.

Ohnishi H, Kosuzume H, Inaba H, Okura M, Morita Y, Mochizuki H, et al. Mechanism of host defense suppression induced by viral infection: mode of action of inosiplex as an antiviral agent. Infect Immun. 1982;38(1):243–250. PubMed PMC

Renoux G, Renoux M, Guillaumin J-M. Isoprinosine as an immunopotentiator. J Immunopharmacol. 1979;1(3):337–356. PubMed

Morin A, Ballet JJ. A recent overview on in vitro and in vivo immunological activities of methisoprinol. Allergol Immunopathol (Madr) 1982;10(2):109–114. PubMed

Gordon P, Brown ER. The antiviral activity of Isoprinosine. Can J Microbiol. 1972;18(9):1463–1470. PubMed

De Simone C, Prohost JW. Antibiosis and host immunity. Boston, MA: Springer; 1987. Prohost modulation of immunity by isoprinosine and NPT 15392; pp. 279–290.

Linhares R, Rebello M, Nozawa C. Effect of isoprinosine on rotavirus replication in vitro. Braz J Med Biol Res. 1996;29(2):219–222. PubMed

Licht K, Hartl M, Amman F, Anrather D, Janisiw MP, Jantsch MF. Inosine induces context-dependent recoding and translational stalling. Nucleic Acids Res. 2019;47(1):3–14. PubMed PMC

Fudenberg HH, Whitten HD. Immunostimulation: synthetic and biological modulators of immunity. Annu Rev Pharmacol Toxicol. 1984;24:147–174. PubMed

Ginsberg T, Hadden J. Immunomodulation. Boston, MA: Springer; 1984. Immunopharmacology of methisoprinol; pp. 331–348.

Campoli-Richards DM, Sorkin EM, Heel RC. Inosine pranobex. Drugs. 1986;32(5):383–424. PubMed

Simon LN, Glasky AJ. Isoprinosine: an overview. Cancer Treat Rep. 1978;62(11):1963–1969. PubMed

Tsang PH, Sei Y, Bekesi JG. Isoprinosine-induced modulation of T-helper-cell subsets and antigen-presenting monocytes (Leu M3 + Ia +) resulted in improvement of T- and B-lymphocyte functions, in vitro in ARC and AIDS patients. Clin Immunol Immunopathol. 1987;45(2):166–176. PubMed

Pompidou A, Delsaux M, Telvi L, Mace B, Coutance F, Falkenrodt A, et al. Isoprinosine and imuthiol, two potentially active compounds in patients with AIDS-related complex symptoms. Cancer Res. 1985;45(9 Supplement):4671s–4673s. PubMed

Cillari E, Dieli M, Lo Campo P, Sireci G, Caffarelli A, Maltese E, et al. Protective effect of isoprinosine in genetically susceptible BALB/c mice infected with Leishmania major. Immunology. 1991;74(1):25–30. PubMed PMC

Janíčková O, Ančicová L, Briestenska K, Mistrikova J. The effect of Isoprinosine treatment on persistent infection of Balb/c mice infected with murine gammaherpesvirus 68. Acta Virol. 2017;61(1):32–38. PubMed

Krastev Z, Jelev D, Ivanova R. Isoprinosine induces a rapid lympho-mononuclear response in adult participants. Med Inf. 2015;2(1):80–85.

Corey L, Chiang W, Reeves W, Stamm W, Brewer L, Holmes K. Effect of isoprinosine on the cellular immune response in initial genital herpes virus infection. Clin Res. 1979;27:41A.

Galbraith GM, Thiers BH, Fudenberg HH. An open-label trial of immunomodulation therapy with inosiplex (Isoprinosine) in patients with alopecia totalis and cell-mediated immunodeficiency. J Am Acad Dermatol. 1984;11(2):224–230. PubMed

Lowy M, Ledoux-Corbusier M, Achten G, Wybran J. Clinical and immunologic response to Isoprinosine in alopecia areata and alopecia universalis: association with autoantibodies. J Am Acad Dermatol. 1985;12(1):78–84. PubMed

Wybran J, Schandené L. Isoprinosine in aphthous stomatitis: clinical improvement associated with enhancement of IL2 production. Int J Immunopharmacol. 1985;7(3):318.

Dabrowska-Bernstein B, Stasiak A, Dabrowski M, Pawinska A, Cianciara J, Loch T, et al. Evaluation of the treatment of chronic active hepatitis (HBsAg +) with isoprinosine II Immunological studies. Pol Tyg Lek. 1990;45(16–18):347–351. PubMed

Cianciara J, Laskus T, Gabinska E, Loch T. Isoprinosine in the treatment of chronic active hepatitis type B. Scand J Infect Dis. 1990;22(6):645–648. PubMed

Schinazi RF, Cannon DL, Arnold BH, Martino-Saltzman D. Combinations of isoprinosine and 3′-azido-3′-deoxythymidine in lymphocytes infected with human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1988;32(12):1784–1787. PubMed PMC

Majewska A, Lasek W, Janyst M, Młynarczyk G. Inhibition of adenovirus multiplication by inosine pranobex and interferon α in vitro. Cent Eur J Immunol. 2015;40(4):395–399. PubMed PMC

Piret J, Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother. 2011;55(2):459–472. PubMed PMC

Gupta R, Warren T, Wald A. Genital herpes. Lancet. 2007;370(9605):2127–2137. PubMed

Looker KJ, Magaret AS, May MT, Turner KME, Vickerman P, Gottlieb SL, et al. Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012. PLoS ONE. 2015;10(10):e0140765. PubMed PMC

Looker KJ, Magaret AS, Turner KME, Vickerman P, Gottlieb SL, Newman LM. Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. PLoS ONE. 2015;10(1):e114989. PubMed PMC

Pinninti SG, Kimberlin DW. Neonatal herpes simplex virus infections. Semin Perinatol. 2018;42(3):168–175. PubMed

Mekki M, Eley B, Hardie D. Wilmshurst JM Subacute sclerosing panencephalitis: clinical phenotype, epidemiology, and preventive interventions. Dev Med Child Neurol. 2019 PubMed

Gutierrez J, Issacson RS, Koppel BS. Subacute sclerosing panencephalitis: an update. Dev Med Child Neurol. 2010;52(10):901–907. PubMed

Tatli B, Ekici B, Ozmen M. Current therapies and future perspectives in subacute sclerosing panencephalitis. Expert Rev Neurother. 2012;12(4):485–492. PubMed

Gadoth N. Subacute sclerosing panencephalitis (SSPE) the story of a vanishing disease. Brain Dev. 2012;34(9):705–711. PubMed

Noetzel MJ, Dodson WE. Progressive CT abnormalities despite clinical improvement in SSPE treated with inosiplex. Ann Neurol. 1983;13(4):457–460. PubMed

Solomon T, Hart CA, Vinjamuri S, Beeching NJ, Malucci C, Humphrey P. Treatment of subacute sclerosing panencephalitis with interferon-alpha, ribavirin, and inosiplex. J Child Neurol. 2002;17(9):703–705. PubMed

Huttenlocher PR, Mattson RH. Isoprinosine in subacute sclerosing panencephalitis. Neurology. 1979;29(6):763–771. PubMed

Silverberg R, Brenner T, Abramsky O. Inosiplex in the Treatment of Subacute Sclerosing Panencephalitis. Arch Neurol. 1979;36(6):374–375. PubMed

DuRant RH, Dyken PR, Swift AV. The influence of inosiplex treatment on the neurological disability of patients with subacute sclerosing panencephalitis. J Pediatr. 1982;101(2):288–293. PubMed

Haddad FS, Risk WS. Isoprinosine treatment in 18 patients with subacute sclerosing panencephalitis: a controlled study. Ann Neurol. 1980;7(2):185–188. PubMed

Jones C, Huttenlocher P, Dyken P, Jabbour JT, Maxwell K. Inosiplex therapy in subacute sclerosing panencephalitis: a multicentre, non-randomised study in 98 patients. Lancet. 1982;319(8280):1034–1037. PubMed

Anlar B, Aydin OF, Guven A, Sonmez FM, Kose G, Herguner O. Retrospective evaluation of interferon-beta treatment in subacute sclerosing panencephalitis. Clin Ther. 2004;26(11):1890–1894. PubMed

Anlar B, Yalaz K, Kose G, Saygi S. Beta-interferon plus inosiplex in the treatment of subacute sclerosing panencephalitis. J Child Neurol. 1998;13(11):557–559. PubMed

Fukuyama Y, Nihei K, Matsumoto S, Ebina T, Kamoshita S, Sato T, et al. Clinical effects of MND-19 (Inosiplex) on subacute sclerosing panencephalitis—a multi-institutional collaborative study—the Inosiplex-SSPE Research Committee. Brain Dev. 1987;9(3):270–282. PubMed

Nasirian A, Ashrafi M, Nasrabady SE. Use of A-interferon, amantadin and isoprinosine in subacute sclerosing panencephalitis (sspe): comparing the effectiveness. Iran J Child Neurol. 2008;2(2):27–32.

Sobczyk W, Kulczycki J, Piłkowska E, Iwińska B, Milewska D, Szmigielski S. Comparison of the results of the treatment of patients with SSPE using various immunomodulating preparations. Neurol Neurochir Pol. 1991;25(5):626–633. PubMed

Aydin ÖF, Şenbil N, Kuyucu N, Gürer YKY. Combined treatment with subcutaneous interferon-α, oral isoprinosine, and lamivudine for subacute sclerosing panencephalitis. J Child Neurol. 2003;18(2):104–108. PubMed

Häusler M, Aksoy A, Alber M, Altunbasak S, Angay A, Arsene OT, et al. A multinational survey on actual diagnostics and treatment of subacute sclerosing panencephalitis. Neuropediatrics. 2015;46(6):377–384. PubMed

Rafique A, Amjad N, Chand P, Zaidi SSZ, Rana MS, Ahmed K, et al. Subacute sclerosing panencephalitis: clinical and demographic characteristics. J Coll Physicians Surg Pak. 2014;24(8):557–560. PubMed

Mohanty CK, Scott SC. Immunotherapy of genital warts with inosine pranobex (Imunovir): preliminary study. Genitourin Med. 1986;62:352–355. PubMed PMC

Sadoul G, Beuret T. Treatment of cervical and vulvar condylomata by CO2 laser also with a immunostimulant. Rev Fr Gynecol Obstet. 1984;79(11):681–684. PubMed

Davidson-Parker J, Dinsmore W, Khan MH, Hicks DA, Morris CA, Morris DF. Immunotherapy of genital warts with inosine pranobex and conventional treatment: double blind placebo controlled study. Genitourin Med. 1988;64(6):383–386. PubMed PMC

Tay SK. Efficacy of inosine pranobex oral therapy in subclinical human papillomavirus infection of the vulva: a randomized double-blinded placebo controlled study. Int J STD AIDS. 1996;7(4):276–280. PubMed

Sand-Petersen C, Weismann K. Isoprenosine improves symptoms in young females with chronic vulvodynia. Acta Derm Venereol. 1996;76(5):404. PubMed

Kedrova AG, Podisov YI, Kuznetsov VV, Bryugzin VV, Kozachenko VP, Nikogosyan SO. Role of antiviral therapy in the complex treatment of patients with epithelial dysplasias and preinvasive cancer of the cervix uteri. Akush Ginekol. 2006;6:27–30.

Georgala S, Katoulis A, Befon A, Georgala C, Rigopoulos D. Short communication: oral inosiplex in the treatment of cervical condylomata acuminata: a randomised placebo-controlled trial. BJOG. 2006;113(9):1088–1091. PubMed

Femiano F, Gombos F, Scully C. Oral proliferative verrucous leukoplakia (PVL); open trial of surgery compared with combined therapy using surgery and methisoprinol in papillomavirus-related PVL. Int J Oral Maxillofac Surg. 2001;30(4):318–322. PubMed

Pachuta DM, Togo Y, Hornick RB, Schwarts AR, Tominaga S. Evaluation of isoprinosine in experimental human rhinovirus infection. Antimicrob Agents Chemother. 1974;5(4):403–408. PubMed PMC

Waldman RH, Ganguly R. Therapeutic efficacy of inosiplex (Isoprinosine®) in rhinovirus infection. Ann N Y Acad Sci. 1977;284(1):153–160. PubMed

Khakoo RA, Watson GW, Waldman RH, Ganguly R. Effect of inosiplex (isoprinosine) on induced human influenza A infection. J Antimicrob Chemother. 1981;7(4):389–397. PubMed

Beran J, Šalapová E, Špajdel M. Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a phase 4, randomised, placebo-controlled, double-blind study. BMC Infect Dis. 2016;16(1):648. PubMed PMC

Lam KC, Lin HJ, Lai CL, Lam SK, Kwan YL. Isoprinosine in classical acute viral hepatitis. Am J Dig Dis. 1978;23(10):893–896. PubMed

Scasso A, Paladini A, Della Santa M. Methisoprinol in the treatment of acute B viral hepatitis: controlled clinical study. BMC Infect Dis. 1983;34(3):423–435.

Nikolova N, Antonov K, Mateva L. Krastev Z Could Inosine pranobex and ribavirin in combination restore immune competence in chronic HCV advanced liver disease? MedInform. 2014;1:35–44.

Pardo M, Carreño V. Lack of efficacy of inosine pranobex in the treatment of chronic hepatitis C. J Hepatol. 1994;21(2):278. PubMed

Wallace JI, Bekesi JG. A double-blind clinical trial of the effects of inosine pranobex in immunodepressed patients with prolonged generalized lymphadenopathy. Clin Immunol Immunopathol. 1986;39(1):179–186. PubMed

Pedersen C, Sandström E, Petersen CS, Norkrans G, Gerstoft J, Karlsson A, et al. the efficacy of inosine pranobex in preventing the acquired immunodeficiency syndrome in patients with human immunodeficiency virus infection. N Engl J Med. 1990;322(25):1757–1763. PubMed

Kovacs JA, Powell F, Voeller D, Allegra CJ. Inhibition of Pneumocystis carinii dihydropteroate synthetase by para-acetamidobenzoic acid: possible mechanism of action of isoprinosine in human immunodeficiency virus infection. Antimicrob Agents Chemother. 1993;37(6):1227–1231. PubMed PMC

De Simone C, Famularo G, Tzantzoglou S, Moretti S, Jirillo E. Inosine pranobex in the treatment of HIV infection: a review. Int J Immunopharmacol. 1991;13(Suppl 1):19–27. PubMed

Georgala S, Katoulis AC, Befon A, Georgala K, Stavropoulos PG. Inosiplex for treatment of alopecia areata: a randomized placebo-controlled study. Acta Derm Venereol. 2006;86(5):422–424. PubMed

Wybran J, Famaey JP, Appelboom T. Inosiplex: a novel treatment in rheumatoid arthritis? J Rheumatol. 1981;8(4):643–646. PubMed

Sadowska-Wroblewska M, Wroblewska-Graff T, Werynska-Przybylska J, Rell-Bakalarska M, Kurdybacha J. Isoprinosine in the early pre-erosive stage of rheumatoid arthritis: a pilot study. Z Rheumatol. 1988;47(2):113–116. PubMed

Becker H, Loers E, Helmke K, Federlin K. Therapy of rheumatic diseases with inosiplex. Immun Infekt. 1986;14(3):93–99. PubMed

Centers for disease control and prevention. What is ME/CFS? 2018. https://www.cdc.gov/me-cfs/about/index.html. Accessed 15 Feb 2019.

World Health Organization . Atlas: multiple sclerosis resources in the world 2008. Geneva: World Health Organization; 2008.

Hommes OR, Comi G. Early indicators early treatments neuroprotection in multiple sclerosis. Milano: Springer; 2004.

Caltagirone C, Carlesimo A. Methisoprinol in the treatment of multiple sclerosis. A pilot study. Acta Neurol Scand. 1986;74(4):293–296. PubMed

Mazzarello P, Rocchelli B, Poloni M, Delodovici M, Pinelli P. Isoprinosine in multiple sclerosis treatment: a preliminary study. Schweiz Arch Neurol Neurochir Psychiatr. 1982;131(2):175–179. PubMed

Pompidou A, Rancurel G, Delsaux M, Meunier C, Telvi L, Cour V, et al. Immunosuppressive effects of isoprinosine in man: a comparison to chlorambucil effects in multiple sclerosis. Cancer Detect Prev Suppl. 1987;1:377–383. PubMed

Milligan NM, Miller DH, Compston DA. A placebo-controlled trial of isoprinosine in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 1994;57(2):164–168. PubMed PMC

World Health Organization. Global tuberculosis report 2018. 2018.

Laurenzi M, Ginsberg A, Spigelman M. Challenges associated with current and future TB treatment. Curr Drug Targets Infect Disord. 2007;7(2):105–119. PubMed

Mishra AK, Yabaji SM, Dubey RK. Evaluation of isoprinosine to be repurposed as an adjunct anti-tuberculosis chemotherapy. Med Hypotheses. 2018;115:77–80. PubMed

Ompico MG. Methisoprinol for children with early phase dengue infection: a pilot study. Paediatr Indones. 2013;53(6):320–327.

Sarciron ME, Delabre I, Walbaum S, Raynaud G, Petavy AF. Effects of multiple doses of isoprinosine on Echinococcus multilocularis metacestodes. Antimicrob Agents Chemother. 1992;36(1):191–194. PubMed PMC

Sarciron ME, Walbaum S. Petavy AF Effects of Isoprinosine on Echinococcus multilocularis and E. granulosus metacestodes. Parasitol Res. 1995;81(4):329–333. PubMed

Lawton P, Walchshofer N, Sarciron M. In vitro effects of isoprinosine and a dipeptide methyl ester on Echinococcus multilocularis protoscoleces. J Helminthol. 2001;75(3):251–257. PubMed

Gascon GG. Randomized treatment study of inosiplex versus combined inosiplex and intraventricular interferon-α in subacute sclerosing panencephalitis (SSPE): international multicenter study. J Child Neurol. 2003;18(12):819–827. PubMed

Nakamura T, Miyasaka N, Pope RM, Talal N, Russell IJ. Immunomodulation by isoprinosine: effects on in vitro immune functions of lymphocytes from humans with autoimmune diseases. Clin Exp Immunol. 1983;52(1):67–74. PubMed PMC

Wiranowska-Stewart M, Hadden JW. Effects of isoprinosine and NPT 15392 on interleukin-2 (IL-2) production. Int J Immunopharmacol. 1986;8(1):63–69. PubMed

Tsang KY, Donnelly R, Galbraith G, Fudenberg HH. Isoprinosine effects on interleukin-1 production in acquired immune deficiency syndrome (AIDS) Int J Immunopharmacol. 1986;8(4):437–441. PubMed

Tsang KY, Fudenberg H, Galbraith G, Donnelly R, Bishop L, Koopmann W. Partial restoration of impaired interleukin-2 production and Tac antigen (putative interleukin-2 receptor) expression in patients with acquired immune deficiency syndrome by isoprinosine treatment in vitro. J Clin Invest. 1985;75(5):1538–1544. PubMed PMC

Silvennoinen-Kassinen S, Karttunen R, Tiilikainen A, Huttunen K. Isoprinosine enhances PHA responses and has potential effect on natural killer cell (NK) activity of uremic patients in vitro. Nephron. 1987;46(3):243–246. PubMed

Hersey P, Bindon C, Bradley M, Hasic E. Effect of isoprinosine on interleukin 1 and 2 production and on suppressor cell activity in pokeweed mitogen stimulated cultures of B and T cells. Int J Immunopharmacol. 1984;6(4):321–328. PubMed

De Simone C, Capozzi C, Campo S, Ricca D, Matteucci G. Effect of azathioprine and inosiplex on rosette formation by lymphocytes from normal donors and from patients with neoplasia. Ann Sclavo. 1981;23:116–124. PubMed

Galli M, Lazzarin A, Moroni M, Zanussi C. Inosiplex in recurrent herpes simplex infections. Lancet. 1982;320(8293):331–332. PubMed

Galli M, Lazzarin A, Moroni M, Zanussi C. Treatment of recurrent viral infectious diseases by methisoprinol. In: Fudenberg HH, Whitten HD, Ambrogi F, editors. Immunomodulation: new frontiers and advances. Boston: Springer; 1984. pp. 385–397.

Talbot DJ, Menday AP, Saurat JH. Inosine pranobex in mucocutaneous herpes. Lancet. 1985;325(8433):877. PubMed

Cutler J, Talbot DJ. The successful treatment of Herpes genitalis with Imunovir (inosine pranobex) 6th International Meeting of the International Society for STD Research; 31st July–2nd August 1985. England: Brighton; 1985.

Byrne M, Lawrence A, Walker G, O’Neill O, Csonka G, John J. Suppression of recurrent genital herpes by inosine pranobex: effects of episodic and continuous treatment. BMC Infect Dis. 1988;43(4):681–688.

Mindel A, Carney O, Sonnex C, Freris M, Patou G, Williams P. Suppression of frequently recurring genital herpes: acyclovir v inosine pranobex. Sex Transm Infect. 1989;65(2):103–105. PubMed PMC

Kinghorn G, Woolley P, Thin R, De Maubeuge J, Foidart J-M, Engst R. Acyclovir vs. isoprinosine (immunovir) for suppression of recurrent genital herpes simplex infection. Sex Transm Infect. 1992;68(5):312–316. PubMed PMC

Feldman S, Hayes FA, Chaudhary S, Ossi M. Inosiplex for localized herpes zoster in childhood cancer patients: preliminary controlled study. Antimicrob Agents Chemother. 1978;14(3):495–497. PubMed PMC

Lesourd B, Laude J, Meunier P, Doumerc S, Moulias R. Isoprinosine treatment of herpes zoster. Results of a control study in 36 subjects. Nouv Presse Med. 1982;11(3):191–193. PubMed

Castelli M, Zanca A, Giubertoni G, Zanca A, Bertolini A. Griseofulvin-methisoprinol combination in the treatment of herpes zoster. Pharmacol Res Commun. 1986;18(10):991–996. PubMed

Payne CMR, Menday AP, Rogers T, Staughton RC. Isoprinosine does not influence the natural history of herpes zoster or postherpetic neuralgia. Scand J Infect Dis. 1989;21(1):15–18. PubMed

Yalaz K, Anlar B, Oktem F, Aysun S, Ustacelebi S, Gurcay O, et al. Intraventricular interferon and oral inosiplex in the treatment of subacute sclerosing panencephalitis. Neurology. 1992;42(3 Pt 1):488–491. PubMed

Gascon G, Yamani S, Crowell J, Stigsby B, Nester M, Kanaan I, et al. Combined oral isoprinosine-intraventricular alpha-interferon therapy for subacute sclerosing panencephalitis. Brain Dev. 1993;15(5):346–355. PubMed

Anlar B, Yalaz K, Oktem F, Kose G. Long-term follow-up of patients with subacute sclerosing panencephalitis treated with intraventricular alpha-interferon. Neurology. 1997;48(2):526–528. PubMed

Gokcil Z, Odabasi Z, Demirkaya S, Eroglu E, Vural O. Alpha-interferon and isoprinosine in adult-onset subacute sclerosing panencephalitis. J Neurol Sci. 1999;162(1):62–64. PubMed

Eroglu E, Gokcil Z, Bek S, Ulas UH, Ozdag MF, Odabasi Z. Long-term follow-up of patients with adult-onset subacute sclerosing panencephalitis. J Neurol Sci. 2008;275(1–2):113–116. PubMed

Zagni G, Cannarozzo C. Clinical trial on the topical application of methisoprinol in some cutaneous viruses. Clin Eur. 1982;21:3–7.

Malgouyat J. A new approach to the treatment of genital condyloma in women. Gynecologie. 1983;34(5):415–517.

Mihula M. Possible treatment of anogenital warts with the immunomodulation agent Isoprinosine. Prakt Gyn. 2015;19(2):101–106.

Nejmark B, Kondrat’eva J, Zologina V, Torbik D. Effectiveness of combined treatment of HPV infection. Urologiia. 2015;2:39–40. PubMed

Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course

Inosine Pranobex Significantly Decreased the Case-Fatality Rate among PCR Positive Elderly with SARS-CoV-2 at Three Nursing Homes in the Czech Republic

See more in PubMed

figshare
10.6084/m9.figshare.8124878